TY - JOUR
T1 - Clinical features related to statin-associated muscle symptoms
AU - Ochs-Balcom, Heather M.
AU - Nguyen, Ly Minh
AU - Ma, Changxing
AU - Isackson, Paul J.
AU - Luzum, Jasmine A.
AU - Kitzmiller, Joseph P.
AU - Tarnopolsky, Mark
AU - Weisman, Michael
AU - Christopher-Stine, Lisa
AU - Peltier, Wendy
AU - Wortmann, Robert L.
AU - Vladutiu, Georgirene D.
N1 - Funding Information:
Abbreviations: CI, confidence interval; CK, creatine kinase; CVD, cardiovascular disease; CYP, cytochrome P450; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; LDLC, LDL-cholesterol; OR, odds ratio; SAMS, statin-associated muscle symptoms; ULN, upper limits of normal. Key words: muscle disease; rhabdomyolysis; risk factors; statin-associated muscle symptoms; statins †Deceased. Funding: This work was supported by grants from the John R. Oishei Foundation; an Interdisciplinary Research and Creative Activities Award from the University at Buffalo Office of the Vice President for Research (to GDV); National Institutes of Health (R01 HL085800 to GDV; R21 AR055704 to PJI); and National Institutes of Health Loan Repayment Program (L30 HL110279 to JAL; NIHK23 GM100372 and R01 MD011307 to JPK). Conflicts of Interest: Dr. Lisa Christopher-Stine has received royalties from Inova Diagnostics for intellectual property interests related to the anti-HMG-CoA reductase assay. All other authors have no conflicts of interest. Correspondence to: H. M. Ochs-Balcom; e-mail: hmochs2@buffalo.edu © 2018 Wiley Periodicals, Inc. Published online 11 January 2019 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mus.26397
Funding Information:
This work was supported by grants from the John R. Oishei Foundation; an Interdisciplinary Research and Creative Activities Award from the University at Buffalo Office of the Vice President for Research (to GDV); National Institutes of Health (R01 HL085800 to GDV; R21 AR055704 to PJI); and National Institutes of Health Loan Repayment Program (L30 HL110279 to JAL; NIHK23 GM100372 and R01 MD011307 to JPK).The authors thank The People's Pharmacy (Joe and Terry Graedon) for assistance in the recruitment of self-referrals. This publication is dedicated to co-author Joseph P. Kitzmiller, M.D., Ph.D., who passed away in October 2018. Dr. Kitzmiller was a kind, dedicated and productive collaborator who will be greatly missed. Ethical Publication Statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2019/5
Y1 - 2019/5
N2 - Introduction: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). Methods: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. Results: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. Discussion: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve 59:537–537, 2019.
AB - Introduction: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). Methods: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. Results: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. Discussion: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve 59:537–537, 2019.
KW - muscle disease
KW - rhabdomyolysis
KW - risk factors
KW - statin-associated muscle symptoms
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=85059857681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059857681&partnerID=8YFLogxK
U2 - 10.1002/mus.26397
DO - 10.1002/mus.26397
M3 - Article
C2 - 30549046
AN - SCOPUS:85059857681
SN - 0148-639X
VL - 59
SP - 537
EP - 543
JO - Muscle and Nerve
JF - Muscle and Nerve
IS - 5
ER -